BACKGROUND Giant cell tumour (GCT) of the bone is a rare, invasive benign bone tumour, which typically originates in the metaphyseal ends of long bones and rarely in the spine. Here, we report a rare case of recurrent GCT of the thoracic vertebra, which was managed by three-level total en bloc spondylectomy (TES) after denosumab therapy. CASE PRESENTATION A 50-year-old woman presented with a 2-month history of progressive lower back pain. Magnetic resonance imaging revealed destruction of the T11 vertebra and a soft tissue mass. The patient underwent tumour resection. Computed tomography at the 2-year follow-up revealed relapse of the resected tumour, which had spread to the T12 vertebral body. Subsequently, denosumab therapy was administered to the patient for 1 year. The growth of the tumour was controlled, and its boundary line was clear. Thereafter, TES for the T10-T12 vertebrae was performed, and spinal reconstruction was completed through a one-stage single posterior approach. The patient's condition improved postoperatively, and no evidence of recurrence of GCT of the bone or spinal deformity was observed at the 32-month follow-up. CONCLUSIONS Denosumab therapy contributed to tumour regression. Three-level TES may be an effective and feasible strategy for managing large recurrent GCTs of the spine after denosumab therapy.

中文翻译：

---

整体整脊椎切除术和denosumab疗法治疗的胸椎复发性巨细胞瘤：1例病例报告。

背景技术骨的巨细胞瘤（GCT）是一种罕见的浸润性良性骨肿瘤，其通常起源于长骨的干phy端，很少起源于脊柱。在这里，我们报告了罕见的胸椎GCT复发病例，该病例由denosumab治疗后通过三级整体整脊椎切除术（TES）处理。病例介绍一名50岁女性，有2个月进行性腰背痛病史。磁共振成像显示T11椎骨和软组织块受到破坏。该患者接受了肿瘤切除术。在2年的随访中，计算机断层扫描显示切除的肿瘤复发，该肿瘤已扩散到T12椎体。随后，对该患者进行denosumab治疗1年。肿瘤的生长得到控制，其边界线清晰。此后，对T10-T12椎骨进行TES，并通过一阶段单后路入路完成脊柱重建。术后患者情况有所改善，在32个月的随访中未观察到骨GCT复发或脊柱畸形的证据。结论Denosumab治疗有助于肿瘤消退。三级TES可能是治疗denosumab治疗后脊柱大面积复发GCT的有效可行策略。结论地诺单抗治疗有助于肿瘤消退。三级TES可能是治疗denosumab治疗后脊柱大面积复发GCT的有效可行策略。结论Denosumab治疗有助于肿瘤消退。三级TES可能是治疗denosumab治疗后脊柱大面积复发GCT的有效可行策略。